Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer

Ström, T.; Cruz, Angie De La; Figura, Nick; Shrinath, Kushagra; Nethers, Kevin; Mellon, Eric A.; Fernandez, Daniel C.; Saini, Amarjit; Hunt, David E.; Heysek, Randy V.; Wilder, Richard B.

doi:10.1016/j.brachy.2015.08.012

Cited by 12 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A few reports have compared LDR-BT with CFRT, and they have commonly indicated that acute GU toxicities were more severe in LDR-BT than in CFRT (8,13). In contrast, in our study, IPSS and QOL scores were worse in the LDR-BT group, while no significant difference was observed in physician-recorded acute GU toxicities between the LDR-BT and EBRT groups.…”

Section: Discussioncontrasting

confidence: 89%

“…To the best of our knowledge, no study has directly compared the five radiotherapy methods for prostate cancer. While a few retrospective studies had already compared HDR-BT with LDR-BT, they showed a slight advantage of HDR-BT, especially regarding acute GU toxicity (5,7,13). These study findings revealed that the HDR-BT group experienced less acute GU toxicity and late GI toxicity than those in the hypofractionated EBRT groups.…”

Section: Discussionmentioning

confidence: 85%

“…While the difference with respect to clinical results (toxicity and efficacy) between UHRT and CFRT continues to gain clarity with more published research (2,11), very few studies have simultaneously compared these radiotherapy methods (12,13). In particular, no direct comparison studies, with adequate data, between HDR-BT as monotherapy and hypofractionated EBRT have been published.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Background/Aim: To compare five radiotherapy methods for prostate cancer. Patients and Methods: During 2005-2018, the data of patients with non-metastatic prostate cancer were retrospectively analysed. Patients were treated with high-dose-rate brachytherapy (HDR-BT); low-dose-rate brachytherapy (LDR-BT); or external-beam radiotherapy (EBRT), including conventionally fractionated radiotherapy (CFRT), moderate-hypofractionated radiotherapy (MHRT), and ultra-hypofractionated radiotherapy (UHRT). Results:

show abstract

Section: Discussioncontrasting

confidence: 89%

Section: Discussionmentioning

confidence: 85%

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…В настоящее время имеется большое количество литературы, подтверждающей эффективность как перманентной брахитерапии, так и брахитерапии с применением временных источников высокой мощности дозы в лечении рака предстательной железы (рПЖ) [3,6,10]. Изначально технология внутритканевой лучевой терапии разрабатывалась в качестве метода, позволяющего подвести дополнительную дозу облучения (boost -добавка (англ.))…”

Section: Introductionunclassified

High-Dose-Rate and Low-Dose-Rate Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer

Солодкий¹,

Pavlov²,

Tsybulskiy³

et al. 2019

Problems in oncology

View full text Add to dashboard Cite

PURPOSE:To compare the outcome of high-dose-rate interstitial brachytherapy (HDR-BT) and low-dose-ratebrachytherapy (LDR-BT) as monotherapy for localized prostate cancer of low and intermediate risks progression. METHODS AND MATERIALS: The study included 165 patients with localized prostate cancer in low and intermediate progression risk groups. We compared 65 patients treated with HDR-BT and 100 patients with LDR-BT as monotherapy. LDR-BT treated advanced disease with more hormonal therapy than HDR-BT. All patients were in low and intermediate risk groups for prostate cancer progression. HDR-BT as monotherapy was delivered in 2 fractions of 15 Gy, two weeks apart. LDR-BT was performed in a standard mode of 145 Gy. The median observation was 32 months. All patients gave written informed consent. RESULTS: Overall biochemical free survival rate (BFSR) is 95,8%. There are 7 people having a growing prostatic specific antigen (PSA) while the case follow-up (in the group HDR-BT - 2 patients, LDR - 5 patients). Two recurrence cases with metastases in lymph nodes and bones were brought out as a result of 68Ga-PSMA PET examination in the group of HDR-BT. In 4 cases out of 5 LDR-BT, a local recurrence was detected (p=0,085). All cases of relapse were found in patients at intermediate risk (p = 0,041). LDR-BT showed a higher incidence of genitourinary (GU) toxicity grade >2 than that of HDR-BT in the acute phase and grade 1 toxicity in late phase. Accumulated incidence of late grade >2 GU and GU toxicity was equivalent between HDR-BT and LDR-BT. CONCLUSION: HDR-BT monotherapy showed an equivalent outcome to that of LDR-BT for low and intermediate risk patients. LDR-BT showed equivalent incidence of grade >2 late GU toxicities and higher grade >2 acute GU toxicity as that of HDR-BT as a monotherapy.

show abstract

“…Prostate cancer is the most common type of cancer among men in the United States [ 1 ]. Low-dose-rate brachytherapy is a treatment option for men with low-risk or favorable intermediate-risk prostate cancer, providing cure rates similar to those of intensity-modulated radiation therapy [ 2 , 3 ] more cost-effectively and with less severe declines in bowel health–related quality of life [ 4 ]. Oncologic outcomes and treatment-related toxicity after low-dose-rate brachytherapy depend greatly on the quality of the implant, which in turn depends on accurate placement and dose distribution of the radioactive seeds.…”

Section: Introductionmentioning

confidence: 99%

Reactive Oxygen Species Generation in Human Cells by a Novel Magnetic Resonance Imaging Contrast Agent

Wang

Lin

Johansen³

et al. 2018

Journal of Toxicology

View full text Add to dashboard Cite

The novel positive-contrast magnetic resonance imaging (MRI) marker C4 consists of an aqueous solution of cobalt chloride (CoCl2) complexed with the chelator N-acetylcysteine (NAC). We evaluated whether the presence of C4 or its components would produce reactive oxygen species (ROS, including hydroxyl, peroxyl, or other reactive oxygen species) in cultured cells. Human cancer or normal cells were incubated with 1% (w/v) CoCl2·6H2O or 2% NAC or a combination of both (1% CoCl2·6H2O : 2% NAC in an aqueous solution, abbreviated as Co : NAC) in the presence or absence of H2O2. Intracellular ROS levels were measured and quantified by change in relative fluorescence units. Student's t-tests were used. In all cell lines exposed to 1000 μM H2O2, the Co : NAC led to ≥94.7% suppression of ROS at 5 minutes and completely suppressed ROS at 60 and 90 minutes; NAC suppressed ROS by ≥76.6% at 5 minutes and by ≥94.5% at 90 minutes; and CoCl2·6H2O suppressed ROS by ≥37.2% at 30 minutes and by ≥48.6% at 90 minutes. These results demonstrate that neither Co : NAC nor its components generated ROS; rather, they suppressed ROS production in cultured cells, suggesting that C4 would not enhance ROS production in clinical use.

show abstract

Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer

Cited by 12 publications

References 42 publications

Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer

Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer

High-Dose-Rate and Low-Dose-Rate Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer

Reactive Oxygen Species Generation in Human Cells by a Novel Magnetic Resonance Imaging Contrast Agent

Contact Info

Product

Resources

About